FGFR1 inhibitor-2 is primarily utilized in the field of cancer research and therapy, specifically targeting cancers driven by fibroblast growth factor receptor (FGFR) signaling. It is employed to inhibit the activity of FGFR1, a receptor tyrosine kinase often implicated in tumor growth and progression. By blocking FGFR1, this compound helps to suppress cell proliferation, angiogenesis, and survival in cancer cells that rely on this pathway. It is particularly relevant in studying and treating cancers such as breast, lung, and bladder cancers, where FGFR1 overexpression or mutations are common. Additionally, it serves as a valuable tool in preclinical studies to understand the role of FGFR signaling in cancer biology and to develop targeted therapeutic strategies.